

**ASSESSMENT OF CHEMOTHERAPY OUTCOME AND
ADVERSE EVENT MANAGEMENT AMONG SOLID
CANCER PATIENTS OF PENANG HOSPITAL**

BASSAM ABDUL RASOOL HASSAN

**UNIVERSITI SAINS MALAYSIA
2013**

**ASSESSMENT OF CHEMOTHERAPY OUTCOME AND
ADVERSE EVENT MANAGEMENT AMONG SOLID
CANCER PATIENTS OF PENANG HOSPITAL**

By

BASSAM ABDUL RASOOL HASSAN

**Thesis submitted in fulfillment of the requirements for the degree of
Doctor of Philosophy
(Pharmacy)**

May 2013

DEDICATION

To

My great family specifically to my lovely father Abdul Rasool and mother Basma.

My darling wife Hiba and my sweet heart daughter Shams.

My great Brothers Rafid and Bilal.

(May Great ALLAH Bless My Soul)

Bassam

ACKNOWLEDGMENTS

This research would not have been possible without the help of those whom I would like to get this chance to thank them from depth of my heart.

I would like to begin by expressing my indebtedness and grateful thanks to the greatest and mercifulness God ALLAH the Almighty for bestowing me and giving me the strength, patience and power to finish this research.

I am delighted to express my great sincere appreciation and heartfelt thanks to my supervisors Associate Professor Dr. Zuraidah Binti Mohd Yusoff, Associate Professor Saad Bin Othman and Associate Professor Dr. Mohamed Azmi Ahmad Hassali for their great guidance, intellectual supports, encouragement and unlimited advices during the different stages of my work.

I'm thankful to my field supervisor Dr. Tan Boon Seang in the Oncology Clinics at Penang Hospital, for his support and help during conducting this research.

I would like to express my grateful thanks and appreciation to University of Sains Malaysia and a special thanks to the School of Pharmaceutical Sciences for offering me the chance to do my postgraduate study.

Also I would like to thank all the medical staff of Penang Hospital especially those who work in the oncology clinic, ward C11, C19 and record office.

I would like to thank to the most and greatest support in my whole life, those who fill my life with all colorful beauties of hope and nature, those who will remain just like my soul, my great and marvelous father, mother, wife, daughter and brothers.

May ALAH (Subhanahu Wa Ta'ala) bless all those who contributed directly or indirectly to success of this research.

TABLE OF CONTENTS

Page		
	TITLE	i
	DEDICATION	ii
	ACKNOWLEDGMENTS	iii
	TABLE OF CONTENTS	iv
	LIST OF TABLES	xxi
	LIST OF FIGURES	xxxii
	LIST OF ABBREVIATIONS	xxxiii
	ABSTRAK	xxxviii
	ABSTRACT	xl
	CHAPTER 1: INTRODUCTION	
	1.1 Cancer Background	1
	1.2 Chemotherapy Background	1
	1.3 Chemotherapy Side Effects	2
	1.4 Main Problems Caused by Solid Cancer Diseases and Chemotherapy	3
	1.4.1 Nausea and Vomiting	3
	1.4.1.1 Causes of Nausea and Vomiting	4
	1.4.1.2 Nausea and Vomiting in Solid Cancer Patients	4
	1.4.1.3 Pathophysiology of Chemotherapy-Induced Nausea and Vomiting	5
	1.4.1.4 Major Patients Risk Factors Associated with Incidence and Severity of Nausea and Vomiting	7

1.4.1.5	Major Chemotherapy Factors Responsible For Incidence and Severity of Nausea and Vomiting	8
1.4.1.6	Classification of Chemotherapy Induced Nausea and Vomiting	9
1.4.1.7	Diagnosis of Incidence of Nausea and Vomiting	10
1.4.1.8	Classification and Incidence of Chemotherapy Induced Nausea and Vomiting	10
1.4.1.9	Grading of Nausea and Vomiting Severity for Acute and Delayed Phase	11
1.4.1.10	Association of Acute Emesis with Delayed Emesis	12
1.4.1.11	Nausea and Vomiting Treatment	12
1.4.1.11.1	Serotonin-Receptor Antagonists (<i>5-HT₃</i>)	13
1.4.1.11.2	Dopamine-2- Receptor Antagonists	13
1.4.1.11.3	Corticosteroids	14
1.4.1.11.4	Neurokinin-1-Receptor Antagonists	14
1.4.1.11.5	Cannabinoids	15
1.4.1.12.6	Benzodiazepines	15
1.4.1.12	Antiemetic guidelines for Acute and Delayed Chemotherapy Induced Nausea and Vomiting	16
1.4.1.13	Nausea and Vomiting in Breast Cancer	16
1.4.1.14	Ethnic Variation Role in Incidence of Nausea and Vomiting	18
1.4.1.15	Literature Review for Nausea and Vomiting	19
1.4.1.16	Literature review in Malaysia	31
1.4.1.17	Problem Statement	34
1.4.2	Anemia	35
1.4.2.1	Red Blood Cell (RBC) and Iron	35
1.4.2.2	Types of Anemia	36
1.4.2.3	Erythropoietin (EPO) Description and Action	37

1.4.2.4	Causes of Anemia of Chronic Diseases (ACD)	37
1.4.2.5	Diagnosis of Anemia	38
1.4.2.6	Grades of Anemia	39
1.4.2.7	Clinical Symptoms of Anemia	39
1.4.2.8	Anemia and Demographic Data	40
1.4.2.8.1	Association of Anemia with Age	40
1.4.2.8.2	Association of Anemia with Gender	41
1.4.2.8.3	Association of Anemia with Race	41
1.4.2.9	Association of Anemia with Cancer	41
1.4.2.10	Association of Anemia with Chemotherapy	42
1.4.2.11	Indications and Options for Anemia Treatments	43
1.4.2.12	Literature Review of Anemia in Cancer Patients	46
1.4.2.13	Literature Review of Studies in Malaysia on Anemia and Cancer	54
1.4.2.14	Problem Statement	55
1.4.3	Thrombocytopenia	56
1.4.3.1	Platelets Morphology and Structure	56
1.4.3.2	Platelets Function	57
1.4.3.3	Thrombopoietin Hormone (TPO)	58
1.4.3.4	Main Causes of Thrombocytopenia	58
1.4.3.5	Association of Thrombocytopenia with Demographic Data	59
1.4.3.6	Association of Thrombocytopenia with Chemotherapy	59
1.4.3.7	Association of Thrombocytopenia with Solid Cancer	60
1.4.3.8	Diagnosis of Thrombocytopenia	60
1.4.3.9	Levels of Thrombocytopenia	61
1.4.3.10	Clinical Symptoms Associated with Thrombocytopenia	61

1.4.3.11	Thrombocytopenia Treatment	62
1.4.3.12	Literature Review for Thrombocytopenia	63
1.4.3.13	Literature Review for Thrombocytopenia in Malaysia	67
1.4.3.14	Problem Statement	68
1.4.3.15	Association of Thrombocytopenia with Neutropenia	68
1.4.4	Hypercalcemia	69
1.4.4.1	Calcium Homeostasis	69
1.4.4.1.1	Kidney Role in Calcium Homeostasis	70
1.4.4.1.2	Gut Role in Calcium Homeostasis	70
1.4.4.1.3	Bone Role in Calcium Homeostasis	71
1.4.4.2	Main Hormones Responsible for Calcium Control	71
1.4.4.3	Causes of Hypercalcemia	72
1.4.4.4	Hypercalcemia Diagnosis	73
1.4.4.5	Hypercalcemia Levels	73
1.4.4.6	Symptoms of Hypercalcemia	74
1.4.4.7	Hypercalcemia Treatment	74
1.4.4.8	Hypercalcemia with Demographic Data	78
1.4.4.9	Mechanisms of Hypercalcemia Occurrence with Malignancy	78
1.4.4.10	Hypercalcemia with Nausea and Vomiting	79
1.4.4.11	Literature Review For Hypercalcemia and Cancer	79
1.4.4.12	Literature Review For Hypercalcemia in Malaysia	85
1.4.4.13	Problem Statement	86
1.5	Rationale of the Study	87
1.6	Objectives of the Study	89
1.6.1	General Primary Objectives	89

1.6.2	Primary Objectives (Descriptive part)	89
1.6.3	Secondary Objectives (Statistical part)	90
1.7	Significance of the Study	91
 CHAPTER TWO: METHODOLOGY		 93
2.1	Study Approval	93
2.2	Main Sections of The Study	93
2.3	Study Design	94
2.4	Prospective Part	
2.4.1	Study Design For Prospective Part	94
2.4.2	Study Population, Sample Size and Sampling Method For Prospective Part	96
2.4.3	Patients Inclusion and Exclusion Criteria For Prospective Part	97
2.4.3.1	General Inclusion Criteria	97
2.4.3.2	Specific Inclusion and Exclusion Criteria For Nausea and Vomiting	98
1-	Inclusion Criteria for Nausea and Vomiting	98
2-	Exclusion Criteria for Nausea and Vomiting	98
2.4.4	Procedure of Collecting Information or Data Collection For Prospective Part	98
2.4.5	Variables For The Prospective Study Nausea and Vomiting	99
2.5	Retrospective Part	100
2.5.1	Study Design For Retrospective Part	100
2.5.2	Study Population, Sample Size and Sampling Method For Retrospective Part	101
2.5.3	Patients Inclusion and Exclusion Criteria For Retrospective Part	102
2.5.3.1	General Inclusion Criteria	102

2.5.3.1.1	Anemia	102
	1- Inclusion Criteria for Anemia	102
	2- Exclusion Criteria for Anemia	102
2.5.3.1.2	Thrombocytopenia	103
	1- Inclusion Criteria for Thrombocytopenia	103
	2- Exclusion Criteria for Thrombocytopenia	103
2.5.3.1.3	Hypercalcemia	104
	1- Inclusion Criteria for Hypercalcemia	104
	2- Exclusion Criteria for Hypercalcemia	104
2.5.4	Procedure of Collecting Information or Data Collection For Retrospective Part	104
2.5.5	Variables For Retrospective Study	105
2.5.5.1	Variables of Anemia	105
2.5.5.2	Variables of Thrombocytopenia	105
2.5.5.3	Variables of Hypercalcemia	105
2.6	Location and Time of the Study	106
2.7	Types of Data Collected and Analysis Process For This Present Study	107
2.8	Statistical Methods	107
CHAPTER 3: RESULTS and DISCUSION		110
3.1	Nausea and Vomiting	111
3.1.1	First Part (Descriptive Part)	111
3.1.1.1	Patient Demographic Data (Patient's Gender, Age and Ethnic Group)	111
3.1.1.2	Breast Cancer Stages	111
3.1.1.3	Chemotherapy	112
3.1.1.3.1	Chemotherapy Emetogenic Level	112
3.1.1.3.2	Chemotherapy Cycles	112

3.1.1.3.3	Chemotherapy Schedule	112
3.1.1.3.4	Chemotherapy Status	113
3.1.1.3.5	Chemotherapy Route of Administration	113
3.1.1.3.6	Time of Chemotherapy Administration	113
3.1.1.3.7	Types of Chemotherapy Regimen	113
3.1.1.4	Patients Data	114
3.1.1.4.1	History of Chemotherapy Induce Nausea and Vomiting in Previous Cycles	115
3.1.1.4.2	Patients Food Types, Eating Habits and Amounts	115
3.1.1.4.3	Patients Work and House Hold Tasks	116
3.1.1.4.4	Patients Consumption of Alcohol	116
3.1.1.4.5	Taking Other Medication	117
3.1.1.5	Nausea and Vomiting Data	118
3.1.1.5.1	Types of Chemotherapy Induce Nausea and Vomiting (CINV)	118
3.1.1.5.2	Classifications and Onset of Nausea	120
3.1.1.5.3	Classifications and Onset of Vomiting	121
3.1.1.5.4	Severity of Acute Nausea	122
3.1.1.5.5	Severity of Delayed Nausea	122
3.1.1.5.6	Severity of Acute Vomiting	123
3.1.1.5.7	Severity of Delayed Vomiting	123
3.1.1.6	Treatment of Nausea and Vomiting	124
3.1.1.6.1	Chemotherapy Status	124
3.1.1.6.2	Chemotherapy Doses	124
3.1.1.6.3	Anti Emetic Schedule	124

3.1.1.6.4	Pre and Post Chemotherapy Anti Emetic	124
3.1.1.7	Clinical Symptoms Association with Nausea and Vomiting	125
3.1.1.8	Effect of Nausea and Vomiting on Patients QOL	126
3.1.A.1.9	Thinking of Stopping Receiving Chemotherapy Treatment	131
3.1.1.10	Usefulness of Antiemetic Treatment Against Acute and Delayed CINV	131
3.1.1.11	When Did The Patients Experience Nausea	133
3.1.1.12	The Time When Nausea and/ or Vomiting was The Worst	134
3.1.1.13	Chemotherapy Doses Used	134
3.1.2	Second Part (Statistical Analysis)	135
3.1.2.1	Analysis for Association Between Onset and Severity of Nausea and Vomiting with Patients Demographic data	135
3.1.2.1.1	Association with Patients Gender	135
3.1.2.1.2	Association with Patients Ethnic Group and Age	135
3.1.2.2	Association Between Onset and Severity of Nausea and Vomiting with Breast Cancer Stages	138
3.1.2.3	Association between Onset and Severity of Nausea and Vomiting with Chemotherapy Data	139
3.1.2.3.1	Association with Emetogenic Level of Chemotherapy	139
3.1.2.3.2	Association with Chemotherapy Cycles	139
3.1.2.3.3	Association with Chemotherapy Schedule	140
3.1.2.3.4	Association with Types of Chemotherapy Regimens	140
3.1.2.4	Association Between Onset and Severity of Nausea and Vomiting with Anti-Emetic Regimens	141
3.1.2.4.1	Association with Pre and Post-Chemotherapy Anti-Emetic	141

3.1.2.5	Association Between Onset and Severity of Nausea and Vomiting with Clinical Symptoms	142
3.1.2.6	Correlation and Association Between Acute and Delayed Nausea and Vomiting with QOL	143
3.1.2.6.1	Correlation Between Severity of Acute Nausea with Nausea Effects on QOL	143
3.1.2.6.2	Association Between Severity Acute Nausea with Nausea Effect on QOL	143
3.1.2.6.3	Correlation Between Severity of Delayed Nausea with Nausea Effects on QOL	144
3.1.2.6.4	Association Between Delayed Nausea with Nausea Effect on QOL	145
3.1.2.6.5	Correlation Between Severity of Acute Vomiting with Acute Vomiting Effects on QOL	145
3.1.2.6.6	Association Between Acute Vomiting with Acute Vomiting Effect on QOL	146
3.1.2.6.7	Correlation Between Severity of Delayed Vomiting with Vomiting Effects on QOL	147
3.1.2.6.8	Association Between Delayed Vomiting with Vomiting Effects on QOL	147
3.1.2.7	Association Between Acute and Delayed Nausea and Vomiting	148
3.1.2.7.1	Association Between Acute and Delayed Nausea	148
3.1.2.7.2	Association Between Acute and Delayed Vomiting	149
3.1.2.8	Association Between Chemotherapy Doses with Acute and Delayed Nausea and Vomiting	149
3.1.2.9	Association Between Usefulness of Antiemetic Treatment with Acute and Delayed Nausea and Vomiting	152
3.1.2.10	Association Between Ethnicity of Patients with Their Selection of Ideas of Usefulness of Antiemetic Treatment	155
3.1.2.11	Association between Types of CINV with Breast Cancer Stages	156
3.1.2.12	Association between Types of CINV with Chemotherapy Data	156

3.1.2.12.1	Association with Emetogenic Level	156
3.1.2.12.2	Association with Chemotherapy Cycle	156
3.1.2.12.3	Association with Chemotherapy Schedule	157
3.1.2.12.4	Association with Chemotherapy Regimens	157
3.1.2.13	Impact of Acute and Delayed Nausea and Vomiting on QOL for Breast Cancer Patients	158
3.1.2.14	Correlation and Association Between Severity of Acute and Delayed CINV With QOL	162
3.1.3	Discussion	164
3.1.3.1	Association of Nausea and Vomiting with Patient Demographic Data	164
3.1.3.1.1	Patients Gender	164
3.1.3.1.2	Patients Ethnic Group	164
3.1.3.1.3	Patient's Age	165
3.1.3.2	Breast Cancer Stages	166
3.1.3.3	Chemotherapy	166
3.1.3.3.1	Chemotherapy Emetogenic Level	166
3.1.3.3.2	Chemotherapy Cycles	167
3.1.3.3.3	Chemotherapy Schedule	168
3.1.3.3.4	Types of Chemotherapy Regimens	169
3.1.3.3.5	Chemotherapy Doses	170
3.1.3.4	Nausea and Vomiting Data	171
3.1.3.4.1	Types of Chemotherapy Induce Nausea and Vomiting (CINV)	171
3.1.3.4.2	Classifications and Onset of Nausea	178
3.1.3.4.3	Classifications and Onset of Vomiting	178

3.1.3.4.4	Severity of Acute and Delayed Nausea and Vomiting	179
3.1.3.5	Treatment of Nausea and Vomiting	180
3.1.3.5.1	Chemotherapy Status	180
3.1.3.5.2	Chemotherapy Doses	181
3.1.3.5.3	Anti Emetic Pre and Post Chemotherapy	181
3.1.3.6	Patients Data	182
3.1.3.7	Clinical Symptoms Association with Nausea and Vomiting	182
3.1.3.8	Effect, Association and Correlation of Nausea and Vomiting on/ with Patients QOL	184
3.1.3.8.1	Effect of Acute and Delayed Nausea and Vomiting on Patients QOL	184
3.1.3.8.2	Association and Correlation Between Acute and Delayed CINV with QOL	185
3.1.3.9	Usefulness of Antiemetic Treatment Against Acute and Delayed CINV	188
3.1.3.10	Thinking to Stop Chemotherapy Treatment	189
3.1.3.11	The Time That Worst Nausea and Vomiting Present	189
3.2	Anemia	196
3.2.1	(Descriptive Part)	191
3.2.1.1	Patients Demographic Data (Patients' Gender, Ethnic and Age Groups)	191
3.2.1.2	Cancer Information	192
3.2.1.2.1	Types of Cancer Diagnosed	192
3.2.1.2.2	Stages of Cancer	193

3.2.1.3	Chemotherapy Data	194
3.2.1.3.1	Patients and Chemotherapy	194
3.2.1.3.2	Types of Chemotherapy Drugs or Regimens	195
3.2.1.3.3	Doses of Chemotherapy regimens	197
3.2.1.4	Anemia Data	199
3.2.1.4.1	Onset or Incidence of Anemia	199
3.2.1.4.2	Severity of Anemia	200
3.2.1.4.3	Levels of Hemoglobin	201
3.2.1.5	Treatment of Anemia	202
3.2.1.5.1	Types of Treatment	203
3.2.1.5.2	Effect of Types of Treatment (Guideline) on Hemoglobin Level	203
3.2.1.6	Clinical Symptoms Associated with Anemia	204
3.2.2	Second Part (Statistical Analysis)	205
3.2.2.1	Association Between Onset and Severity of Anemia with Patients Demographic Data	205
3.2.2.2	Association with Cancer Data	206
3.2.2.2.1	Association with Cancer Type and Stages	206
3.2.2.3	Association with Chemotherapy Data	208
3.2.2.3.1	Association with Chemotherapy Cycles, Schedule and Chemotherapy Type and Regimen	208
3.2.2.3.2	Association with Chemotherapy Doses	210
3.2.2.4	Association Between Anemia Treatment with Anemia Onset, Severity and Hemoglobin Levels	214
3.2.2.5	Association Between Clinical Symptoms with Anemia Onset and Severity	217
3.2.3	Discussion	219

3.2.3.1	Association of Anemia with Patient Demographic Data	219
3.2.3.1.1	Patients Gender	219
3.2.3.1.2	Patients Ages	219
3.2.3.1.3	Patients Ethnic Group	220
3.2.3.2	Association with Cancer Data	221
3.2.3.2.1	Association with Cancer Type	221
3.2.3.2.2	Association with Cancer Stages	222
3.2.3.3	Association with Chemotherapy Data	224
3.2.3.3.1	Association with Chemotherapy Cycles	224
3.2.3.3.2	Association with Chemotherapy Schedule	226
3.2.3.3.3	Association with Type of Chemotherapy	226
3.2.3.3.4	Association with Chemotherapy Doses	228
3.2.3.4	Association Between Anemia Treatment with Anemia Onset, Severity and Hemoglobin Levels	233
3.2.3.5	Association Between Clinical Symptoms with Anemia Onset and Severity	238
3.3	Thrombocytopenia	240
3.3.1	Descriptive Part	240
3.3.1.1	Patient Demographic Data (Patients Gender, Ethnic Group and Patient's Age)	240
3.3.1.2	Cancer Information	241
3.3.1.2.1	Types of Cancer Diagnosed	241
3.3.1.2.2	Stages of Cancer	241
3.3.1.3	Chemotherapy Data	242
3.3.1.3.1	Patients and Chemotherapy	242
3.3.1.3.2	Types of Chemotherapy Drugs or Regimens	244

3.3.1.3.3	Doses of Chemotherapy Regimens	246
3.3.1.4	Thrombocytopenia Data	248
3.3.1.4.1	Onset of Thrombocytopenia	248
3.3.1.4.2	Severity of Thrombocytopenia	249
3.3.1.4.3	Levels of Platelets	250
3.3.1.4.4	Bleeding Characteristic	251
3.3.1.5	Treatment of Thrombocytopenia	251
3.3.1.5.1	Pattern of Treatment and Chemotherapy Status	251
3.3.1.5.2	Type of Treatments	252
3.3.1.5.3	Effect of Types of Treatment (Guideline) on Platelets Level	253
3.3.1.6	Clinical Symptoms Associated with Thrombocytopenia	254
3.3.1.7	Thrombocytopenia Patients with Neutropenia	254
3.3.2	Second Part (Statistical Analysis)	256
3.3.2.1	Association Between Onset and Severity of Thrombocytopenia With Patients Demographic Data	256
3.3.2.1.1	Association With Patients Gender, Age and Race	256
3.3.2.2	Association with Cancer Information	258
3.3.2.2.1	Association with Cancer Type and Stages	258
3.3.2.3	Association with Chemotherapy Data	259
3.3.2.3.1	Association with Chemotherapy Cycles, Schedule and Types	259
3.3.2.3.2	Association with Chemotherapy Doses	261
3.3.2.4	Association Between Thrombocytopenia Treatment with Thrombocytopenia Onset, Severity and Platelets levels	265
3.3.2.5	Association Between Clinical Symptoms with Thrombocytopenia Onset and Severity	268

3.3.3	Discussion	270
3.3.3.1	Analysis of Association Between Onset and Severity of Thrombocytopenia with Patient Demographic Data	270
3.3.3.2	Association Between Onset and Severity of Thrombocytopenia and Cancer Information	271
3.3.3.2.1	Association with Cancer Type and Stages	271
3.3.3.3	Association with Chemotherapy Data	272
3.3.3.3.1	Association with Chemotherapy Cycles	272
3.3.3.3.2	Association of Thrombocytopenia with Chemotherapy Schedule	274
3.3.3.3.3	Association of Thrombocytopenia with Chemotherapy Types	274
3.3.3.3.4	Association with Chemotherapy Doses	279
3.3.3.4	Association Between Thrombocytopenia Treatment with Thrombocytopenia Onset, Severity and Platelets levels	281
3.3.3.5	Association Between Clinical Symptoms with Thrombocytopenia Onset and Severity	285
3.3.3.6	Patients with Thrombocytopenia and Neutropenia	286
3.4	Hypercalcemia	287
3.4.1	First Part (Descriptive Part)	287
3.4.1.1	Patient Demographic Data (Patients Gender, Ethnic Group and Age Group)	287
3.4.1.2	Cancer Information	288
3.4.1.2.1	Types of Cancer Diagnosed	288
3.4.1.2.2	Stages of Cancer	288
3.4.1.2.3	Types of Lung Cancer	289
3.4.1.2.4	Metastasis of Solid Cancer	289
3.4.1.3	Chemotherapy Data	290
3.4.1.3.1	Chemotherapy Status, Schedule and Types of Chemotherapy Regimens	290
3.4.1.3.2	Doses of Chemotherapy Regimens	294

3.4.1.4	Hypercalcemia Data	295
3.4.1.4.1	Onset of Hypercalcemia	295
3.4.1.4.2	Severity of Hypercalcemia and Level of Calcium Level	296
3.4.1.5	Treatment of Hypercalcemia	297
3.4.1.5.1	Pattern of Treatment	297
3.4.1.5.2	Types of Treatment	297
3.4.1.5.3	Effect of Types of Treatment (Guideline) on Calcium Level	298
3.4.1.5.4	Bone Scan	299
3.4.1.6	Clinical Symptoms Associated With Hypercalcemia	300
3.4.1.7	Hypercalcemia Effect on Biochemistry Profile	301
3.4.2	Second Part (Statistical Analysis)	303
3.4.2.1	Association Between Onset and Severity of Hypercalcemia with Patients Demographic data	303
3.4.2.1.1	Association with Patients Gender, Ethnic Group and Age Group	303
3.4.2.2	Association with Cancer Information	304
3.4.2.2.1	Association with Cancer Type and Stages	304
3.4.2.3	Association with Chemotherapy Data	306
3.4.2.3.1	Association with Chemotherapy Type	306
3.4.2.3.2	Association of Cancer Stages and Metastasis with Chemotherapy Type	307
3.4.2.3.3	Association of Cancer Stages (primary and advanced) with Chemotherapy Doses	310
3.4.2.4	Association of Hypercalcemia with Clinical Symptoms	314
3.4.2.5	Association of Hypercalcemia with Biochemistry Profile	316
3.4.2.6	Association Between Hypercalcemia Treatment with Hypercalcemia Onset and Severity	317
3.4.2.7	Sub Types of Lung Cancer	318
3.4.3	Discussion	319

3.4.3.1	Association Between Onset and Severity of Hypercalcemia with Patients Demographic Data	319
3.4.3.1.1	Association with Patients Gender	319
3.4.3.1.2	Association with Patients Race	319
3.4.3.1.3	Association with patients Ages	321
3.4.3.2	Association with Cancer Information	321
3.4.3.2.1	Association with Cancer Type	321
3.4.3.2.2	Association with Cancer Stages	322
3.4.3.3	Association with Chemotherapy Data	325
3.4.3.3.1	Association with Chemotherapy Type	325
3.4.3.3.2	Association of Cancer Stages and Metastasis with Chemotherapy Type	328
3.4.3.3.3	Association of Cancer Stages (Primary and Advanced i.e., Metastases) and Calcium Level with Chemotherapy Doses	335
3.4.3.4	Association of Hypercalcemia with Clinical Symptoms	339
3.4.3.5	Association of Hypercalcemia with Biochemistry Profile	341
3.4.3.6	Association Between Hypercalcemia Treatment with Hypercalcemia Onset and Severity	342
3.4.3.7	Sub Types of Lung Cancer	345
CHAPTER 4: CONCLUSION, RECOMMENDATIONS AND LIMITATIONS		346
4.1	Conclusion	346
4.2	Recommendations	349
4.3	Limitations	351
REFERENCES		352
APPENDICES		387
LIST OF PUBLICATIONS		403

LIST OF TABLES

Table No.	Title	Page
Table 1.1	Grading of Chemotherapy Induced Nausea and Vomiting Severity for Both Acute and Delayed	11
Table 1.2	Antiemetic Guideline for Acute and Delayed Nausea and Vomiting	16
Table 1.3	Clinical Tests Used to Differentiate ACD From IDA	39
Table 1.4	Grades of Anemia	39
Table 1.5	Clinical Signs and Symptoms Associated with Anemia	40
Table 3.1	Demographic Data of Breast Cancer Patients Admitted to Oncology Clinic, Ward C11 and C19 (n=158) Who Experienced Nausea and Vomiting	111
Table 3.2	Breast Cancer Stages of Patients Admitted to Penang Hospital who Suffered From Nausea and Vomiting (n=158)	111
Table 3.3	Chemotherapy Cycles at Which Nausea and Vomiting Occurred (n=158)	112
Table 3.4	Chemotherapeutics Drugs or Regimens Used (n=158) to Treat The Breast Cancer Patients	113
Table 3.5	Breast Cancer Patients Data (n=158)	114
Table 3.6	History of Chemotherapy Induced Nausea and Vomiting in Previous Chemotherapy Cycles (n=133)	115
Table 3.7	Food Consumption, Eating Habits and Amount Eating by Breast Cancer Patients (n=158) on Chemotherapy	116
Table 3.8	Effect of Nausea and Vomiting on Patients (n=158) Work and House Hold Tasks	116
Table 3.9	Consumption and Pattern of Consumption of Alcohol Among Breast Cancer Patients (n=158) Who Experienced Nausea and Vomiting	117

Table 3.10	Nausea and Vomiting Effect on Consumption of Other Medication Among Breast Cancer Patients (n=158)	117
Table 3.11	Types of Chemotherapy Induce Nausea and Vomiting (CINV) Observed in 158 Breast Cancer Patients	118
Table 3.12	Types of Chemotherapy Induce Nausea and Vomiting (CINV) Among Chinese Patients (n=101)	119
Table 3.13	Types of Chemotherapy Induce Nausea and Vomiting (CINV) Among Malay Patients (n=35)	119
Table 3.14	Types of Chemotherapy Induce Nausea and Vomiting (CINV) Seen in Indian Patients (n=22)	120
Table 3.15	Classification and Onset of Nausea Among Breast Cancer Patients (n=158)	121
Table 3.16	Classification and Onset of Vomiting among Breast Cancer Patients (n=158)	121
Table 3.17	Severity of Acute Nausea Among Breast Cancer Patients (n=158)	122
Table 3.18	Severity of Delayed Nausea Among Breast Cancer Patients (n=158)	122
Table 3.19	Severity of Acute Vomiting Among Breast Cancer Patients (n=158)	123
Table 3.20	Severity of Delayed Vomiting Among Breast Cancer Patients (n=158)	123
Table 3.21	Different Types of Clinical Symptoms Observed in Breast Cancer Patients (n=137) who Suffered from Nausea and Vomiting in Penang Hospital	125
Table 3.22	Scores of Acute Nausea Effect on Quality of Life (QOL) of Breast Cancer Patients (n=158)	126
Table 3.23	Scores of Acute Vomiting Effect on Quality of Life (QOL) of Breast Cancer Patients (n=158)	127
Table 3.24	Scores of Delayed Nausea Effect on Quality of Life (QOL) of Breast Cancer Patients (n=158)	128

Table 3.25	Scores of Delayed Vomiting Effect on Quality of Life (QOL) of Breast Cancer Patients (n=158)	129
Table 3.26	Effect of CINV on Quality of Life (QOL) of Breast Cancer Patients (n=158)	130
Table 3.27	Patients Thinking of Stop Chemotherapy Treatment (n=158)	131
Table 3.28	Usefulness of Antiemetic Treatment Against Acute and Delayed Nausea and Vomiting (n=158)	132
Table 3.29	Time of Experiencing Nausea and Vomiting (n=158)	133
Table 3.30	The Time When Nausea and/ or Vomiting was The Worst (n=158)	134
Table 3.31	Chemotherapy Doses Used (n=158)	135
Table 3.32	Statistical Analysis of The Ethnic Group and Patient's Age with Nausea and Vomiting	137
Table 3.33	Statistical Analysis of the Cancer Stages with Nausea and Vomiting	138
Table 3.34	Statistical Analysis of the Chemotherapy Cycles with Nausea and Vomiting	139
Table 3.35	Statistical Analysis of the Chemotherapy Regimens with Nausea and Vomiting	140
Table 3.36	Statistical Analysis of the Pre- and Post- Chemotherapy Antiemetic with Nausea and Vomiting	141
Table 3.37	Statistical Analysis of the Clinical Symptoms with Nausea and Vomiting	142
Table 3.38	Statistical Analysis for Correlation Between the Severity of Acute Nausea with Nausea Effect on QOL	143
Table 3.39	Statistical Analysis of the Acute Nausea with Nausea Effect on QOL	144
Table 3.40	Statistical Analysis for Correlation Between the Severity of Delayed Nausea with Delayed Nausea Effect on QOL	144
Table 3.41	Statistical Analysis of the Delayed Nausea with Delayed Nausea Effect on QOL	145

Table 3.42	Statistical Analysis for Correlation Between the Severity of Acute Vomiting with Acute Vomiting Effect on QOL	146
Table 3.43	Statistical Analysis of the Acute Vomiting with Acute Vomiting Effect on QOL	146
Table 3.44	Statistical analysis for Correlation Between the Severity of Delayed Vomiting with Delayed Vomiting Effect on QOL	147
Table 3.45	Statistical Analysis of the Delayed Vomiting with Vomiting Effects on QOL	148
Table 3.46	Statistical Analysis of Association Between Onset and Severity of Acute Nausea with Severity of Delayed Nausea (n=158)	148
Table 3.47	Statistical Analysis of Association Between Onset and Severity of Acute Vomiting with Severity of Delayed Vomiting (n=158)	149
Table 3.48	Association Between Chemotherapy Doses with Acute and Delayed Nausea and Vomiting	150
Table 3.49	Logistic Regression Test of Chemotherapy Doses with Onset and Severity of Acute and Delayed Nausea and Vomiting	151
Table 3.50	Statistical Analysis of Association Between Perception of Patients on the Usefulness of Antiemetic Treatment Against Acute and Delayed Nausea and Vomiting (n=158)	153
Table 3.51	Logistic Regression Analysis of Perception of Patients on the Usefulness of Antiemetic Treatment Against Acute and Delayed Nausea and Vomiting (n=158)	154
Table 3.52	Association Between Cancer Patients Races with Opinions of Usefulness of Antiemetic Treatments Against Acute and Delayed CINV (n=158)	155
Table 3.53	Statistical Analysis Results of Association Between CINV and Breast Cancer Stages	156
Table 3.54	Statistical Analysis Results of Association Between CINV and Chemotherapy Cycles	157
Table 3.55	Statistical Analysis Results of Association Between CINV and Chemotherapy Regimen	158
Table 3.56	Impact Effect of Acute CINV on Breast Cancer Patients QOL (n=158)	159

Table 3.57	Impact of Delayed Nausea and Vomiting on QOL for Breast Cancer Patients	161
Table 3.58	The Correlation and Association of Severity of Acute and Delayed of CINV with Impact Effect of Acute and Delayed CINV on Breast Cancer QOL (n=158)	163
Table 3.59	Gender, Ethnic and Age Group of Cancer Patients with Anemia (n=534) Admitted to the Oncology Ward From 2003-2009	191
Table 3.60	Types of Cancer Diagnosed Among Anemic Patients Admitted to Penang Hospital Between 2003-2009 (n=534)	193
Table 3.61	Cancer Stages Among the Anemic Patients Admitted (n=534)	194
Table 3.62	Chemotherapy Data of Anemic Patients (n=534) Admitted to Ward C19 Between 2003-2009	194
Table 3.63	Types of Chemotherapy Used in Anemic Patients (n=408) Admitted to Ward C 19 Between 2003-2009	196
Table 3.64	Chemotherapy Doses Administered to Anemic Patients	198
Table 3.65	Onset or Incidence of Anemia Detected Among Cancer Patients Before Chemotherapy (n=126)	199
Table 3.66	Onset of Anemia Among Cancer Patients After Chemotherapy Administration (n=408)	200
Table 3.67	Severity of Anemia among Cancer Patients Prior to Chemotherapy Administration (n=126)	201
Table 3.68	Severity of Anemia Which Developed After Chemotherapy (n=408) Among Cancer Patients Admitted to Ward C19	201
Table 3.69	The level of Hemoglobin Among the Cancer Patients with Anemia Admitted to Ward C19 Between 2003-2009	202
Table 3.70	Anemia Treatment (n=534) Employed for the Cancer Patients with Anemia and Chemotherapy Status	202
Table 3.71	Types of Treatment Used for Anemia (n=534)	203
Table 3.72	Effect of Anemia Treatments Guidelines on Hemoglobin Level for Anemic Patients in Penang Hospital (n=534)	204
Table 3.73	Clinical Symptoms Associated with Anemia (n=2091)	205

Table 3.74	Association Between Patient Demographic Data with Anemia Onset and Severity (n=534)	206
Table 3.75	Association Between Types and Stages of Solid Cancers with Onset and Severity of Anemia Before and After Chemotherapy (n=534)	207
Table 3.76	Association Between Chemotherapy Cycles, Schedules and Types with Anemia Onset and Severity	209
Table 3.77	Logistic Regression of Chemotherapy Regimens with Anemia Onset (n=408)	209
Table 3.78	Logistic Regression of Chemotherapy Regimens with Anemia Severity (n=408)	210
Table 3.79	Correlation of Chemotherapy Doses with Anemia Onset (n=408)	211
Table 3.80	Correlation of Chemotherapy Doses with Anemia Severity (n=408)	212
Table 3.81	Liner regression of Chemotherapy Doses with Anemia Onset (n=408)	213
Table 3.82	Liner Regression of Chemotherapy Doses with Anemia Severity (n=408)	213
Table 3.83	Association of Anemia Treatment with Onset and Severity of Anemia Before and After Chemotherapy	215
Table 3.84	Association of Anemia Treatment with Hemoglobin Levels Onset and Severity Before and After Chemotherapy	215
Table 3.85	Logistic Regression Test Between Anemia Treatment with Anemia Severity and Hb Levels	216
Table 3.86	Association of Clinical Symptoms with Onset and Severity of Anemia	217
Table 3.87	Logistic Regression of Clinical Symptoms with Anemia Onset and Severity	217
Table 3.88	Demographic Data of Thrombocytopenic Patients Admitted to Penang Hospital (n=341)	240
Table 3.89	Types of Cancer Diagnosed Among Thrombocytopenic Patients Studied (n=341)	241

Table 3.90	Cancer Stages When Thrombocytopenia Occurred Among Patients Studied (n=341)	242
Table 3.91	Chemotherapy Data for Thrombocytopenic Patients (n=341)	243
Table 3.92	Types of Chemotherapy Used in Thrombocytopenic Patients (n=320)	245
Table 3.93	Chemotherapy Doses Administered to Thrombocytopenic Patients	247
Table 3.94	Onset of Thrombocytopenia Among Cancer Patients Before Chemotherapy (n=21)	248
Table 3.95	Onset of Thrombocytopenia Among Cancer Patients After Chemotherapy (n=320)	249
Table 3.96	Thrombocytopenia Severity Among Cancer Patients Before Chemotherapy (n=21)	249
Table 3.97	Thrombocytopenia Severity Among Cancer Patients After Chemotherapy (n=320)	250
Table 3.98	Platelets Levels Found Among Thrombocytopenic Patients (n=341)	250
Table 3.99	Degree of Bleeding Happened With Severe Thrombocytopenia Patients (n=51)	251
Table 3.100	Thrombocytopenia Treatment Pattern (n=51)	252
Table 3.101	Effect of Thrombocytopenia Treatments Guidelines on Platelets Level for Thrombocytopenic Patients in Penang Hospital (n=274)	253
Table 3.102	Clinical Symptoms Associated With Thrombocytopenia (n=1311)	254
Table 3.103	Incidence of Thrombocytopenia After Receiving G-CSF (filgrastim)	255
Table 3.104	Association Between Patient Demographic Data with Thrombocytopenia Onset and Severity (n=341)	257
Table 3.105	Association Between Solid Cancer Types and Stages with Onset and Severity of Thrombocytopenia Before and After Chemotherapy	259

Table 3.106	Association Between Chemotherapy Cycles, Schedules and Types with Thrombocytopenia Onset and Severity	260
Table 3.107	Logistic Regression of Chemotherapy Regimens with Thrombocytopenia Onset	260
Table 3.108	Logistic Regression of Chemotherapy Regimens with Thrombocytopenia Severity	261
Table 3.109	Correlation of Chemotherapy Doses with Thrombocytopenia Onset	262
Table 3.110	Correlation of Chemotherapy Doses with Thrombocytopenia Severity	263
Table 3.111	Linear Regression of Chemotherapy Doses with Thrombocytopenia Onset	264
Table 3.112	Linear Regression of Chemotherapy Doses with Thrombocytopenia Severity	264
Table 3.113	Association of Thrombocytopenia Treatment with Onset and Severity of Thrombocytopenia Before and After Chemotherapy	266
Table 3.114	Association of Thrombocytopenia Treatment with Platelets Levels Onset and Severity Before and After Chemotherapy	266
Table 3.115	Association of Treatment with Thrombocytopenia and Platelets Levels Severity After Chemotherapy	267
Table 3.116	Association of Clinical Symptoms with Onset and Severity of Thrombocytopenia	268
Table 3.117	Logistic Regression of Clinical Signs with Thrombocytopenia Onset and Severity	269
Table 3.118	Demographic Data of Hypercalcemic Patients Admitted to Penang Hospital (n=292)	287
Table 3.119	Types of Cancer Diagnosed Among Hypercalcemic Patients Studied (n=292)	288
Table 3.120	Breast (n=174) and Lung (n=118) Cancer Stages During The Occurrence of Hypercalcemia	288

Table 3.121	Types of Lung Cancer Associated with Hypercalcemia (n=118)	288
Table 3.122	Breast and Lung Cancer Metastasis (n=292)	288
Table 3.123	Chemotherapy Status, Schedules and Types of Regimens Received by Patients Who Developed Hypercalcemia (n=292)	290
Table 3.124a	Effect of Chemotherapy Regimens on Breast and Lung Cancer Size and Metastasis (cancer size depend on cT= clinical staging)	291
Table 3.124b	Effect of Chemotherapy on Calcium Levels of Breast and Lung Cancer with Hypercalcemia (HC)	292
Table 3.125	Chemotherapy Doses Received by Hypercalcemic Patients	295
Table 3.126	Onset of Hypercalcemia Among Cancer Patients (n=292)	296
Table 3.127a	Severity of Hypercalcemia Among Cancer Patients (n=292)	296
Table 3.127b	Calcium Level Among Hypercalcemic Patients (n=292)	297
Table 3.128	Hypercalcemia Treatment Pattern (n=292)	297
Table 3.129	Types of Treatment Used for Hypercalcemia (n=292)	298
Table 3.130	Effects of Types of Treatment on Calcium Level	299
Table 3.131	Bone Scan Performed Among Hypercalcemic Patients (n=292)	300
Table 3.132	Clinical Symptoms Associated with Hypercalcemia	301
Table 3.133	Biochemistry Profile Changes in Presence of Hypercalcemia	302
Table 3.134	Effects of Hypercalcemia on Cancer Patients Biochemistry Profile	302
Table 3.135	Association of Hypercalcemia Onset and Severity with Patients Demographic Data (n=292)	303
Table 3.136	Logistic Regression Test of Gender and Race Association with Hypercalcemia Onset	304
Table 3.137	Association of Cancer Types and Stages with Hypercalcemia Onset and Severity	305

Table 3.138	Logistic Regression for Association of Hypercalcemia Onset with Breast and Lung Cancer (n=292)	305
Table 3.139	Logistic Regression for Association of Hypercalcemia Onset with Breast and Lung Cancer Stages (n=292)	306
Table 3.140	Association of Type of Chemotherapy with Onset and Severity of Hypercalcemia (n=292)	306
Table 3.141	Logistic Regression for Association of Chemotherapy Types with Hypercalcemia Onset and Severity	307
Table 3.142	Association of Chemotherapy Type with Cancer Stages	308
Table 3.143	Logistic Regression for Association of Chemotherapy Types with Early and Advanced Cancer Stages	308
Table 3.144	Association of Chemotherapy Types with Solid Cancer Sizes/ Differences Between Calcium Level Before and After Chemotherapy Uses	309
Table 3.145a	Logistic Regression of Chemotherapy Types with Solid Cancer Sizes (Breast)	309
Table 3.145b	Logistic Regression of Chemotherapy Types with Solid Cancer Sizes (Lung)	309
Table 3.146	Correlation of chemotherapy Doses with Cancer Stages (primary and advanced based on cancer size in cm) (n=292)	310
Table 3.147	Association of Chemotherapy Doses with Cancer Stages (primary and advanced) (n=292)	311
Table 3.148a	Correlation of Chemotherapy Doses with Calcium Level	312
Table 3.148b	Association of Chemotherapy Doses with Calcium Level	313
Table 3.149	Association of Clinical Symptoms with Hypercalcemia Onset and Severity	314
Table 3.150	Logistic Regression for Association of Clinical Symptoms with Hypercalcemia Onset	315
Table 3.151	Logistic Regression for Association of Clinical Symptoms with Hypercalcemia Severity	315
Table 3.152	Association of Biochemistry Profile with Hypercalcemia Onset and Severity	316

Table 3.153	Logistic for Biochemistry Profile Association with Hypercalcemia Severity	317
Table 3.154	Association of Treatment with Hypercalcemia Onset and Severity (n=292)	318
Table 3.155	Logistic Regression for Treatment Used in Severe Hypercalcemic Patients (n=292)	318

LIST OF FIGURES

Title	Page
Figure 1.1: Responsible Neurotransmission Pathways for Chemotherapy Induce Nausea and Vomiting (CINV)	6

LIST OF ABBREVIATIONS

µg	Micro gram
µl	Microliter
dl	Deciliter
Kg	Kilogram
gm (g)	Gram
L	Litter
mg	Milligram
m ²	Square Meter
ml	Milliliter
U	Unit
1 st cycle	First Cycle
2 nd cycle	Second Cycle
3 rd cycle	Third cycle
4 th cycle	Fourth cycle
5 th cycle	Fifth cycle
6 th cycle	Sixth cycle
ACD	Anemia of Chronic Diseases
ADH	Antidiuretic Hormone
ANS	Autonomic Nervous System
aPTT	Thromboplastin Time
ASCO	American Society of Clinical Oncology
ASHP	American Society of Health-System Pharmacist
ATP	Adenosine Triphosphate

CAF	Cyclophosphamide, Adriamycin and 5-Flourouracil
cAMP	Cyclic Adenosine Monophosphate
CBC	Complete Blood Count
cDNA	Cyclic Deoxyribonucleic Acid
CEF or FEC	Cyclophosphamide + Epirubicin + 5-Flourouracil
CFU-E	Colony Forming Unit-Erythroid
CINV	Chemotherapy Induce Nausea and Vomiting
CMV	Cytomegalovirus
CNS	Central Nervous System
CMF	Cyclophosphamide + Methotrexate + 5-Flourouracil
CRC	Clinical Research Centre
CT	Computed Tomography
CTZ	Chemoreceptor Trigger Zone
CYP	Cytochrome P450 Enzymes
DNA	Deoxyribonucleic Acid
D2	Dopamine-2 Receptor
ECAS	European Cancer Anaemia Survey
ESA	Erythropoiesis-Stimulating Agents
EPO	Erythropoietin
ESR	Erythrocyte Sedimentation Rate
FAO	Food and Agriculture Organization
FDA	United State Federal and Drug Administration (FDA)
FLIE	Functional Living Index- Emesis (FLIE) Questionnaire
GIT	Gastrointestinal Tract
Hb	Hemoglobin
HC	Hypercalcemia

Hct	Hematocrit
HEC	Highly Emetogenic Chemotherapy
HHM	Humoral Hypercalcemia of Malignancy
HIT	Heparin Induced Thrombocytopenia
HPE	Histopathological Examination
IDA	Iron Deficiency Anemia
IDIS	Medline and Iowa Drug Information Services
IMR	Institute for Medical Research
INF- γ	Interferon
IHM	Institute for Health Management
IHBR	Institute for Health Behavioral Research
IHSR	Institute for Health Systems Research
IPH	Institute of Public Health
ITP	Idiopathic Thrombocytopenic Purpura
I.V.	Intravenous
LOH	Local Osteolytic Hypercalcemia
MASCC	Multinational Association of Supportive Care in Cancer
MANE	The Morrow Assessment of Nausea and Emesis
MCV	Mean Corpuscular Volume
MEC	Moderately Emetogenic Chemotherapy
Meg-CFC	Megakaryocyte Colony Forming Cells
MOH	Ministry of Health of Malaysia
MRI	Magnetic Resonance Imaging
NCCN	National Comprehensive Cancer Network
NIH	National Institutes of Health
NICE	National Institute for Clinical Excellence

NK-1	Neurokinin Receptors
ONEM	The Osoba Nausea and Emesis
PO or p.o.	Per Oral
PONV	Postoperative Nausea and Vomiting
PS	Power and Sample Size Program
PT	Prothrombin Time
PTH	Parathyroid Hormone
PTHrP	Parathyroid Hormone-Related Protein
QOL	Quality Of Life
RBC	Red Blood Cells
rhIL-11	Recombinant Human Interleukin-11
rhTPO	Recombinant Human Thrombopoietin
rHuEPO	Recombinant Erythropoietin
RNA	Ribonucleic Acid
r_s	Spearman Correlation coefficient ()
SCF	Stem Cell Factor
SCC	Squamous Cell Carcinoma
SCCOHT	Small Cell Carcinoma of The Ovary and Hypercalcemic Type
TB	Tuberculosis
TNF- α	Tumor Necrosis Factor
TPO	Thrombopoietin
TT	Thrombin Time
TTP	Thrombotic Thrombocytopenic Purpura
UNICEF	United Nations International Children's Emergency Fund
USA	United State of America
USM	Universiti Sains Malaysia

VC	Vomiting Center
WBC	White Blood Cell
WHO	World Health Organization

PENILAIAN HASIL KEMOTERAPI DAN PENGURUSAN PERISTIWA ADVERS DI KALANGAN PESAKIT KANSER PEPEJAL HOSPITAL PULAU PINANG

ABSTRAK

Dalam abad ini, kanser telah menjadi salah satu masalah dan penyakit utama yang telah menyebabkan banyak kematian dan akan melebihi penyakit jantung. Penyakit kanser dan rawatan kemoterapi mempunyai banyak kesan sampingan yang berbahaya yang boleh menjejaskan kualiti hidup (QOL) pesakit-pesakit kanser.

Oleh itu kajian ini dilakukan untuk mengesan faktor-faktor risiko utama berkaitan dengan loya dan muntah, anemia, trombositopenia dan hiperkalsemia dan untuk menilai keberkesanan garis panduan rawatan masing-masing. Di samping itu QOL pesakit kanser payudara yang mengalami loya dan muntah juga dinilai. Kajian prospektif dan retrospektif telah dijalankan keatas pesakit-pesakit kanser pepejal yang dimasukkan ke Hospital Pulau Pinang. Data telah dikumpulkan dengan menggunakan kaedah temuduga secara bersemuka untuk bahagian prospektif (loya dan muntah-muntah) dan dengan menggunakan lembaran data khusus untuk bahagian retrospektif (anemia, trombositopenia dan hiperkalsemia). Maklumat telah dikumpul daripada fail-fail pesakit yang disimpan di klinik onkologi dan pejabat rekod hospital.

Kajian prospektif tertumpu terhadap faktor-faktor risiko dan QOL pesakit kanser payudara (n=158) yang mengalami loya dan muntah setelah rawatan kemoterapi. Faktor-faktor risiko ini termasuk data demografik pesakit, maklumat kanser payudara, data kemoterapi, data ciri-ciri pesakit dan rawatan loya dan muntah. Faktor-faktor utama berkaitan dengan loya dan muntah aruhan kemoterapi (CINV) tertanggung dan akut ialah etnik pesakit, kitaran dan jenis kemoterapi serta rawatan pra dan pasca antiemetik yang digunakan. CINV tertanggung mempunyai kesan negatif terhadap QOL pesakit kanser

payudara yang lebih besar berbanding kesan CINV akut. Di samping itu, kajian menunjukkan bahawa terdapat kepincangan dalam garis panduan rawatan antiemetik yang mungkin disebabkan oleh perbezaan etnik dikalangan pelbagai bangsa.

Bahagian kedua adalah kajian retrospektif observasional ke atas pesakit kanser yang dimasukkan ke hospital di antara tahun 2003 dan 2009 yang mengalami anemia atau trombositopenia atau hiperkalsemia. Menurut kajian ini, faktor risiko utama berkaitan dengan anemia, trombositopenia dan hiperkalsemia adalah jenis dan tahap penyakit kanser; jenis kemoterapi; skedul kemoterapi, kitaran kemoterapi dan dos (tinggi) kemoterapi serta rawatan. Satu lagi hasil kajian penting yang diperolehi berkaitan dengan anemia (n=534 pesakit) ialah garis panduan rawatan yang digunakan adalah tidak cukup berkesan dan hanya bersifat sementara. Hasil kajian yang sama turut diperolehi untuk trombositopenia (n=341 pesakit) dan hiperkalsemia (n=292 pesakit), menunjukkan garis panduan rawatan tidak berkesan. Oleh yang demikian, garis panduan rawatan dan cadangan-cadangan baru digubal berdasarkan daripada hasil kajian ini.

Katakunci: Loya dan Muntah, Loya dan Muntah Tertangguh, Loya dan Muntah Akut, QOL, Anemia, Trombositopenia, Hiperkalsemia, Garis Panduan Rawatan.

ASSESSMENT OF CHEMOTHERAPY OUTCOME AND ADVERSE EVENT MANAGEMENT AMONG SOLID CANCER PATIENTS OF PENANG HOSPITAL

ABSTRACT

During this century, cancer has become one of the major problem and diseases which has caused predominant death and will even surpass heart diseases. Both cancer diseases and chemotherapy have many hazardous side effects which could also affect the quality of life (QOL) of cancer patients.

Thus this study was performed to detect the main risk factors associated with nausea and vomiting, anemia, thrombocytopenia and hypercalcemia and to evaluate effectiveness of respective treatment guidelines. In addition QOL of breast cancer patients with nausea and vomiting was also evaluated. Prospective and retrospective studies were conducted on solid cancer patients admitted to Penang, Hospital. Data were collected by using direct person-to-person interview for the prospective part (nausea and vomiting) and by using specific data sheet for the retrospective part (anemia, thrombocytopenia and hypercalcemia). The required data were collected from patients' files kept in the oncology clinic and the record office of the hospital.

The prospective study focused on risk factors and QOL of breast cancer patients (n=158) suffering from nausea and vomiting after chemotherapy administration. These risk factors include patient's demographic data, breast cancer information, chemotherapy data, patients' characteristic data and treatment of nausea and vomiting. The main risk factors associated with delayed and acute chemotherapy induced nausea and vomiting (CINV) are patients ethnicity, chemotherapy cycles and types, as well as pre and post antiemetic treatments used. As for the effect on QOL, delayed CINV has a higher negative effect on breast cancer patients QOL than acute CINV. Moreover it shows that there is a defect in the antiemetic treatment guideline which might be due to ethnic variation among the different races.

The second part is an observational retrospective study among solid cancer patients admitted between 2003 and 2009 who developed anemia or thrombocytopenia or hypercalcemia. According to this study, the main risk factors associated with anemia, thrombocytopenia and hypercalcemia are types and stages of solid cancer disease, chemotherapy type, chemotherapy schedule, chemotherapy cycle, and chemotherapy dose (high) as well as the treatment. Other important result related to anemia (n=534 patients) is that the treatment guidelines employed is not effective enough and was only temporary. Similar findings were obtained with thrombocytopenia (n= 341 patients) and hypercalcemia (n= 292 patients), indicating ineffectiveness of treatment guideline. Thus new treatment guidelines and recommendations are developed based on the findings.

Keywords: Nausea and Vomiting, Acute Nausea and Vomiting , Delayed Nausea and Vomiting, QOL, Anemia, Thrombocytopenia, Hypercalcemia, Treatment Guidelines.

CHAPTER 1

INTRODUCTION

1.1 Cancer Background

During this century, cancer has become one of the major problem and diseases which has caused predominant death and it will even surpass heart diseases. Many of the researchers begin to use the term lifetime risk for cancer patients which refer to the time that cancer will progress and developed or the time that the patient will die because of cancer. Cancer does not represents only one disease but it is a group involving about 100 diseases. Cancer is characterized by two things. Firstly there is no control for the growth of cancer cells and secondly is the ability of the cancer cells to metastasis and migrate from the original site to different parts of the body. There are two types of tumors which are malignant and benign cancer. Cancer can attack any person and its occurrence increases as the age of the individual increase too (Carson-De Witt, 2002; Markman, 2002). There are many problems (i.e., side effects) associated with cancer diseases either solid or hematological cancer such as nausea, vomiting, diarrhea, constipation, hypercalcemia, pain, lost of appetite, anemia, fatigue, cachexia, leucopenia, neutropenia and thrombocytopenia. However the major problems are nausea and vomiting, neutropenia, anemia, thrombocytopenia and hypercalcemia. Hence due to these reasons cancer is considered as one of the major diseases that will effect the quality of life (Dolan, 2005; Henry, 2005; Sitamvaram, 2005; Stephens, 2005).

1.2 Chemotherapy Background

Chemotherapy was developed and used since the Word War I from the chemical weapon program of the United State of America (USA). Since then chemotherapy has became as one of the most important and significant treatment of cancer. Its main

mechanism of action is by killing the cancer cells which are characterized by their high multiplication and growth rate. It will also kill all the cancer cells that had broken off from the main tumor and spread to the blood or lymphatic system or any part of the body. This killing process of cells is either by a direct effect on deoxyribonucleic acid (DNA) or an effect on the factors involved in mitosis by inhibition of its synthesis or production or uses (Weir-Hughes, 2005; Scurr *et al.*, 2005; Kelland, 2005). Chemotherapy drug may lead to complete cure for some types of cancers or may suppress the growth of others or may prevent their spread to other parts of the body. So many types of new therapies have emerged over the past 20 years. Some of them were straight forward, effective and safe and some have many side effects. However when comparing chemotherapy with other types of treatments, it still remain potentially high risk with many side effects which are difficult to manage. Chemotherapy used required the involvement of various clinical professionals during its various stages of administration and enormous patient health care is needed to overcome its side effects (Weir-Hughes, 2005; Rizzo and Closs, 2002).

1.3 Chemotherapy Side Effects

The goal of chemotherapy is to be as effective as possible with tolerable side effects, since the dose of chemotherapy will be toxic to the cancer cells as well as to the normal cells. A proportion of the cancer patients suffer from only mild side effects whereas others may suffer from serious side effects (Abrams, 2001; Koda-Kimble *et al.*, 2002; Rizzo and Cloos, 2002). These side effects are classified as:

- 1- Acute, which develop within 24 hours after chemotherapy administration.
- 2- Delayed, which developed after 24 hours and up to 6 to 8 weeks after chemotherapy treatments.
- 3- Short term, combination of both acute and delayed effect.
- 4- Late/ long term, which developed after months or years of chemotherapy treatment.
- 5- Expected, which developed among 75% of the patients.

- 6- Common, occurred in 25%-75% of the patients.
- 7- Uncommon, happened is less than 15% of the patients.
- 8- Rare, occur in only 5% of the patients.
- 9- Very rare, occur with less than 1% of the patients (Abrams, 2001; Koda-Kimble *et al.*, 2002; Rizzo and Cloos, 2002).

Occurrence of specific side effects will vary according to the chemotherapy used. The most common side effects experienced are nausea and vomiting, anemia, hair lost, bleeding, thrombocytopenia, hyperuricemia, bone marrow depression, alopecia and mucositis. So different parameters must be taken into consideration to prevent, reduce and overcome these side effects (Abrams, 2001; Koda-Kimble *et al.*, 2002; Rizzo and Cloos, 2002).

1.4 Main Problems Caused by Solid Cancer Diseases and Chemotherapy

1.4.1 Nausea and Vomiting

Both nausea and vomiting are recognized as two separate and distinct conditions. Nausea is an unpleasant sensation of being vomit or urge to vomit which may or may not result in vomiting. While, vomiting or emesis is the process of expelling of digested and undigested food through the mouth. Nausea and vomiting can arises from a different or wide spectrum of etiologies which are either directly associated to cancer disease itself or its treatment. According to the new ranking of chemotherapy side effects, nausea is the number one or the most disturbing side effect, followed by fatigue, neutropenia, anemia or thrombocytopenia, hair losing while vomiting is the third and sometimes the fifth disturbing chemotherapy side effects. Even so, not all cancer patients suffer from nausea and/ or vomiting because not all of them were treated with emetogenic chemotherapy (Haggert, 1999; Oberleitner, 2002; Coates *et al.*, 1983; Lebourgeois *et al.*, 1999; Morrow *et al.*, 2005; Hesketh, 2005; Rudd and Andrews, 2005).

1.4.1.1 Causes of Nausea and Vomiting

There are several factors involved in the stimulation of nausea and vomiting and these factors included stress, pregnancy, motion sickness, migraine headache, cancer stages, radio therapy and chemotherapy.

The main focus of this part of the study will be on the factors causing nausea and vomiting related with solid cancers specifically breast cancer and chemotherapy. Nausea and vomiting is one of the major problems that is associated with cancer patients and 50%-55% of cancer patients suffer from both nausea and vomiting even with the use of antiemetic drugs. The main causes for this are either due to the chemotherapy or because of the cancer progression. Some of the cancer patients who were treated with chemotherapy did not suffer from nausea or vomiting because the chemotherapy used were not significantly emetogenic. Nausea and vomiting still remain the major side effects that occur and is associated with chemotherapy and cancer diseases (Haggerty, 1999; Oberleitner, 2002; Mitchell and Schein, 1984; Bartlett and Koczwara, 2002).

1.4.1.2 Nausea and Vomiting in Solid Cancer Patients

Both nausea and vomiting are very common problems especially with advanced stages of solid cancer diseases like breast cancer and stomach cancer where 50 to 60% of the patients are mainly female under 65 years of age (Molassiotis and Böjeson, 2006). In this situation, nausea and vomiting occur because of the advanced stages of solid cancer diseases characterized by more severe complications than that caused by chemoradiotherapy or other treatments. The main causes for those problems are gastric stasis, obstruction of the intestine, opioid use, constipation caused by morphine uses, hypercalcemia, brain metastasis, renal failure, hyponatremia, increases in the intracranial pressure and tumor burden (Molassiotis and Böjeson, 2006). With regards to solid tumor burden, breast cancer causes nausea and vomiting especially at its advance stages is by metastasis to the abdomen (mainly stomach or liver) or central nervous system (CNS). So emphasis on the details of the effect of advance

stages of cancer on nausea and vomiting should be made which up to now was given only little attention (Molassiotis and Böjesson, 2006).

1.4.1.3 Pathophysiology of Chemotherapy-Induced Nausea and Vomiting

Chemotherapy cause nausea by stimulating the autonomic nervous system (ANS), while vomiting is triggered when afferent impulses from chemoreceptor trigger zone (CTZ), pharynx, cerebral cortex and vagal afferent fiber stimulate the vomiting center (VC) located in the medulla. The stimulation of the VC leads to contraction of muscles of abdomen, chest wall and diaphragm, so this will lead to an expulsion of stomach and intestine contents (Haggerty, 1999; Oberleitner, 2002; Mitchell and Schein, 1984; Bartlett and Koczwara, 2002; Navari, 2007). Nausea and vomiting associated with surgery, chemotherapeutic agents, radiotherapy and pregnancy are thought to be induced by stimulating the dopamine-2 (D₂), acetylcholine, histamine, and serotonin-3 (5-HT₃) neuro-receptors involved in activating specific areas of the brain that coordinate the act of vomiting (Beckley, 2005). Also some studies have reported the involvement of neurokinin receptors (NK-1) especially in delayed emesis, while histamine and muscarinic receptors have lesser role in emesis associated with motion sickness (Hesketh *et al.*, 2003; Grunberg and Hesketh, 1993). The main mechanism of chemotherapy induced vomiting is the stimulation of the enterochromaffin cells lining the wall of the gastrointestinal tract (GIT) hence causes the release of the serotonin. The serotonin will then bind to the vagal afferent 5-HT₃ receptors in the GIT which will send impulses to the CTZ and VC. This is illustrated in Figure 1.1.




Figure 1.1 Responsible Neurotransmission Pathways for Chemotherapy Induce Nausea and Vomiting (CINV) (ASHP, 1999).

1.4.1.4 Major Patients Risk Factors Associated with Incidence and Severity of Nausea and Vomiting

Direct factors associated are: gender, age, history of motion sickness, history of vomiting during pregnancy, history of alcohol consumption and patient anxiety (Haggerty, 1999; Oberleitner, 2002; Hesketh, 2001; Osoba *et al.*, 1997; Hesketh, 2005; Rubenstein, 2005).

When comparing between men and women, women have 2-3 fold higher chance of emesis or need for use of antiemetic prophylaxis treatment within the first 24 hours after receiving high dose of highly emetogenic chemotherapy. While in case of moderate emetogenic chemotherapy drugs, women have significantly lower response rate than men to 5-HT₃ antagonist either when it given as single or combination treatment with dexamethasone, for prevention or protection against emesis or freedom from nausea within the first 24 hours after chemotherapy administration. Other serious and important risk factor is the age, where by younger cancer patients are characterized by poor response to the antiemetic prophylaxis. When comparing the cancer patients according to their ages the results showed that higher percentage of the younger patients suffered from nausea and vomiting than older patients. In some studies the patients were grouped into those more than 55 years old and those less than 55 years old. In these studies the results showed that all patients more than the mean age of the study population showed lower risk of nausea and emesis with the chemotherapy. Also patients who suffered from nausea and vomiting of other etiologies are more susceptible to nausea and vomiting due to chemotherapy treatment. Emesis during pregnancy is consider as one of the risk factor for chemotherapy induce nausea and vomiting (CINV) but the evidence for it is still limited. Alcohol consumption has been indicated as one of protective factors against progress of CINV, however many factors are associated with alcohol consumption and thus this is still not clear whether heavy alcohol consumption (> 100 g/ day) is a protective factor itself or it will cause genetic change leading to protection from emesis. Some authors think that the chronic consumption of alcohol lead to lower sensitivity of chemoreceptor trigger zone to emetic stimuli (Hesketh, 2005). Patient anxiety is a predictive

factor for occurrence and development of delayed and anticipatory emesis. This is because anxiety stimulates the forebrain areas (cortex and limbic system) thus reduce the threshold which will make other inputs induce emesis easily (Hesketh, 2005).

1.4.1.5 Major Chemotherapy Factors Responsible For Incidence and Severity of Nausea and Vomiting

There are several chemotherapeutic factors that play a major role in the incidence and severity of both nausea and vomiting which are:

- 1- Emetogenic potential of the drug
- 2- Dosage level
- 3- Schedule of administration
- 4- Route of administration
- 5- History of previous chemotherapy
- 6- Rate of I.V infusion (Haggerty, 1999; Oberleitner, 2002; Hesketh, 2001; Hesketh, 2005; Ballatori and Roila, 2005).

According to the emetogenic potential, chemotherapy drugs are classified as severe, high, moderate, low and very low depending on the percentage of the cancer patients developing nausea and vomiting. Even with the low emetogenic potential chemotherapeutic drugs, there is still the chance of inducing nausea and vomiting when high doses are given. Another example whereby the emetogenic potential is affected by chemotherapy doses is with cisplatin. Cisplatin dose higher than $50\text{mg}/\text{m}^2$ will lead to 100% occurrence of emesis if antiemetic prophylaxis is not given. Cyclophosphamide is a moderate emetogenic drug when the dose used is between $500\text{-}750\text{ mg}/\text{m}^2$ but is a highly emetogenic drug when the dose is higher than $1500\text{ mg}/\text{m}^2$ (Haggerty, 1999; Oberleitner, 2002; Hesketh, 2001; Hesketh, 2005; Ballatori and Roila, 2005). Schedule of administration especially when various drugs are administered together, will also lead to significant implications for clinical action and toxicity, which i.e., either increases or decreases toxicity or efficacy. This is because this schedule will have an effect on the pharmacokinetic, biochemical and cell related interactions example when cisplatin administration precedes paclitaxel, it will cause

antagonism in their action, while when sequence is inversed this will lead to synergistic effect and will lead to increase in the toxicity of the two drugs i.e., increases in their myelotoxicity, nausea and vomiting effect and other side effects. These are due to the pharmacokinetic interactions of both drugs (Haggerty, 1999; Oberleitner, 2002; Hesketh, 2001; Hesketh, 2005; Ballatori and Roila, 2005).

It is very important that there must be good control on emesis from the first cycle of the chemotherapy. This is because patients who experienced emesis with early stages of chemotherapy treatment will have poor response toward antiemetic treatments in the later cycles. Also response to the antiemetic prophylaxis will gradually decline over time with chemotherapy cycles and about 30% of the patients will develop emesis at the fourth cycle of chemotherapy. Rate of chemotherapy administration is another important factor related with incidence of emesis. This is seen with doxorubicin which is a moderate emetogenic agent, but became less emetogenic when given by continuous infusion and became highly emetogenic when given in more rapid rate of bolus dose (Haggerty, 1999; Oberleitner, 2002; Hesketh, 2001; Hesketh, 2005; Ballatori and Roila, 2005; Scurr *et al.*, 2005).

1.4.1.6 Classification of Chemotherapy Induced Nausea and Vomiting

This classification is based on the emetogenic potential of the chemotherapeutic drug.

- 1- Severe (90% of the patients will experience nausea and vomiting) Example: Cisplatin I.V ≥ 50 mg/ m², Cyclophosphamide I.V > 1500 mg/ m² and Dacarbazine.
- 2- High (60%-90%) Example: Carboplatin, Cisplatin I.V < 50 mg/ m², Cyclophosphamide I.V 750 mg/ m² to 1500 mg/ m² and Cytarabine I.V > 1 gm/ m².
- 3- Moderate (30%-60%) Example: Altretamine I.V PO dose, Asparaginase, Cyclophosphamide (I.V) ≤ 750 mg/ m², Cyclophosphamide PO dose, Doxorubicin (I.V) 20 to 60 mg/ m², and Ifosfamide.
- 4- Low (10%-30%) Example: Capecitabine PO dose, Docetaxel, Doxorubicin liposomal, Fluorouracil and Gemcitabine.

- 5- Very low (less than 10%) Example: Bleomycin, Busulfan PO dose, Methotrexate < 50mg/ m² (Hesketh, 2000; Rubenstein, 2005).

1.4.1.7 Diagnosis of Incidence of Nausea and Vomiting

The diagnosis of nausea and vomiting is based on different parameters mainly severity, frequency of occurrence and duration of symptoms associated with nausea and vomiting (Haggerty, 1999; Oberleitner, 2002).

1.4.1.8 Classification and Incidence of Chemotherapy Induced Nausea and Vomiting

CINV are clinically classified as:

- 1- Acute chemotherapy related nausea and vomiting
- 2- Delayed emesis
- 3- Anticipatory emesis (Hesketh, 2005; KRIS *et al.*, 1985; Haggerty, 1999; Oberleitner, 2002).

Acute emesis is defined as nausea and/ or vomiting or both that occurred within the first 24 hours after chemotherapy administration. It has very important characteristic which is the arbitrary time frame of 24 hours and according to this emesis most commonly occur within one to two hours. The peak of the emesis is within four to six hours and after which emesis will start to subside.

Delayed emesis include nausea and/ or vomiting happening after 24 hours of chemotherapy administration. Delayed emesis is best characterized by cisplatin administration whereby the emesis peaks within four to six hours and then subsides within the next 12 to 16 hours i.e., the acute phase. Then after 24 hours of quiescent period emesis will become obvious again, reaching its peak within 48 to 72 hours and this is the delayed phase. Usually this type of delayed emesis is less intensive than acute emesis and will

resolved in the next two to three days. Many chemotherapy other than cisplatin such as carboplatin, anthracyclines and cyclophosphamide can cause delayed emesis.

Anticipatory emesis happens in patients who already suffered from acute and delayed emesis during the previous cycles. There are many causes and factors which can cause anticipatory emesis prior to chemotherapy cycles. However if acute and delayed emesis are well controlled, anticipatory emesis within the next few years became a much less significant problem (Hesketh, 2005; Oberleitner, 2002).

1.4.1.9 Grading of Nausea and Vomiting Severity for Acute and Delayed Phase

Several numerical grading have been used to clarify the severity of nausea and vomiting as shown in Table 1.

Table 1.1: Grading of Chemotherapy Induced Nausea and Vomiting Severity for Both Acute and Delayed

Grade of severity	Grade 1	Grade 2	Grade 3	Grade 4	Grade5
Nausea	Loss of appetite without alter in eating habit	Oral intake decreases without significant weight loss, dehydration I.V fluids given < 24 hr	Inadequate oral fluids and calories intake, on I.V fluids, tube feeding or on TPN ≥24 hr	Life threatening consequences	Death
Vomiting	1 episode in 24 hours	2-5 episodes in 24 hr; I.V fluids indicated < 24 hr	≥6 episodes in 24 h; IV fluids, or TPN indicated ≥24 h	Life-threatening consequences	Death

(Cancer therapy evaluation program VERSION 3.0, 2008).

1.4.1.10 Association of Acute Emesis with Delayed Emesis

Nausea and vomiting are not independent phenomena, they are both strictly correlated with each other in both acute and delayed phase. It has been found that delayed emesis is mainly dependent on acute episode so when emesis happens in the first cycle of chemotherapy administration (acute phase) then it will be absolutely observed in the delayed phase. Many studies have shown that patients with good protection against emesis during the first cycle of chemotherapy (acute phase) will show a low probability of delayed emesis with subsequent cycles (Ballatori and Roila, 2005). Incidence of delayed emesis is in the range of 50% to 90% in those patients who have poor control of emesis in their early chemotherapy cycles, as compare to about 10% to 50% in those who have good control of emesis in their early cycles (Rubenstein, 2005).

1.4.1.11 Nausea and Vomiting Treatment

The main goal of the antiemetic treatment is to abolish nausea and vomiting which in the last twenty years is consider as an inevitable chemotherapy side effects. This prevention is focused on the entire period of emetic risk which is 4 days for patients who received highly or moderately emetogenic chemotherapy (Navari, 2007; Jordan *et al.*, 2005). This could be perfectly achieved by understanding the mechanisms of these antiemetic drugs either alone or in combination so as to get their maximum benefit (Grunberg and Dugan, 2005). Modern antiemetic treatments help in preventing 70%-80% of nausea and vomiting problems. Combination antiemetic treatment becomes the standard regimen used for the control of nausea and vomiting caused by chemotherapy (Grunberg and Dugan, 2005). The different types of treatments are as follows:

- 1- Serotonin-receptor antagonists (*5-HT₃*)
- 2- Dopamine-2-receptor antagonists
- 3- Corticosteroids
- 4- Neurokinin-1-recptor antagonists
- 5- Cannabinoids

6- Benzodiazepines (Jordan *et al.*, 2005).

1.4.1.11.1 Serotonin-Receptor Antagonists (5-HT₃)

These agents are one of the most effective antiemetic treatment for acute nausea and vomiting caused by chemotherapy, even for the acute nausea and vomiting resulting from highly emetogenic chemotherapy like cisplatin. They selectively block the 5-HT₃ receptor in the periphery (visceral vagal afferent fiber) and in the brain (CTZ) (Jordan *et al.*, 2005; Oberleitner, 2002; Haggerty, 1999). These agents have specific characteristics as described below:

- 1- The lowest effective dose should be used because high doses will lead to saturation of receptors and will not lead to any enhancement in the antiemetic activity.
- 2- Both oral and intravenous route will give similar action.
- 3- Single dose is as effective as multiply doses regimens.
- 4- The adverse effects of these agents are acceptable (Jordan *et al.*, 2005).

The 5-HT₃ antagonist drugs most commonly used are dolasetron (Anzemet[®]), granisetron (Kytril[®]) and ondansetron (Zofran[®]). These three drugs are found to be similar in their effect and side effect. Both ondansetron and granisetron can prevent 50%-60% of the emesis caused by the highly emetogenic chemotherapy (i.e., cisplatin). The effective dose for this are dolasetron (I.V= 1.8 mg/ kg, oral= 100 mg, PO= 100 mg), ondansetron (I.V= 0.15 mg/ kg or 8-24 mg, PO= 12-24 mg) and granisetron (I.V= 0.01 mg/ kg or 1 mg, PO= 2mg) (Kris *et al.*, 1985; De Mulder *et al.*, 1990; Hesketh *et al.*, 1996; Cubbedu *et al.*, 1990; Navari *et al.*, 1995; Howland and Mycek, 2006).

1.4.1.11.2 Dopamine-2- Receptor Antagonists

These agents were the main agents for antiemetic therapy from 1950s until 1980s. However, their efficacy as single agents is low compared with other agents. These agents produce their antiemetic effect through blocking of the dopamine receptors in the CTZ and

VC. This antiemetic class is divided into butyrophenones (e.g., droperidol and haloperidol), phenothiazines (e.g., prochlorperazine) and substituted benzamides (e.g., metoclopramide). conventional dose of metoclopramide is effective in treating with emesis due to mild to moderate emetogenic chemotherapy. While in case of highly emetogenic chemotherapy like cisplatin, metoclopramide need to be given in high doses so it will produce its antiemetic effect by antagonism at the 5HT₃ receptors. The high doses for metoclopramide is 1-2 mg/kg which can be given for 6-8 times per day to a maximum dose of 12 mg/ day. The adverse effects especially when receiving high doses of these agents include orthostatic hypotension, extrapyramidal symptoms and sedation (ASHP, 1999; Kovac, 2000; Jordan *et al.*, 2005; Ison and Peroutka, 1986).

1.4.1.11.3 Corticosteroids

Their mechanism of action as antiemetic is still unclear and not fully understood but are considered as safe and effective antiemetic. They exert their effect through prostaglandin antagonist or immunosuppressive effect. They act as a booster when use in combination with other antiemetic agents (e.g., metoclopramide and ondansetron) by increasing the emetic threshold. Dexamethasone has been vastly investigated and used for treatment of acute emesis. A dose of 8mg will be effective for moderately emetogenic chemotherapy and 20 mg is required for severely emetogenic chemotherapy (MASCC, 2004; The Italian Group for Antiemetic Research, 1998; The Italian Group for Antiemetic Research, 2004; Hesketh *et al.*, 1994; Kovac, 2003; Jordan *et al.*, 2005).

1.4.1.11.4 Neurokinin-1-Receptor Antagonists

They represent a new class of antiemetic agents. Aprepitant penetrate through blood brain barrier and selectively block the NK-1 receptor. It has been approved by United State Federal and Drug Administration (FDA) as an effective oral antiemetic drug which is very effective in preventing acute and delayed emesis due to high emetogenic chemotherapy (e.g., cisplatin or cisplatin base therapy). Several studies had proven that aprepitant augmented the

action of dexamethasone and 5-HT₃ combination in inhibiting acute and delayed emesis but specifically delayed emesis of highly emetogenic chemotherapy drugs. While for moderate emetogenic chemotherapy many studies showed that triple combination of aprepitant + dexamethasone + 5-HT₃ receptor antagonist show superiority in the first 24 hours followed by aprepitant for the next 2 days alone. MASCC and NCCN guidelines both indicated the effectiveness of aprepitant plus 5-HT₃ plus dexamethasone for the treatment of moderate chemotherapeutics drugs. The appropriate doses of aprepitant with acceptable side effects are 125 mg orally (p.o.) on day one and 80 mg (p.o.) on day 2 and 3. Since aprepitant is metabolized by CYP3A4 then dexamethasone dose must be reduced to about 50% when aprepitant is co administered in order to overcome any drug interaction (Jordan *et al.*, 2005; Poli-Bigelli *et al.*, 2003; Herrstedt, 2005).

1.4.1.11.5 Cannabinoids

The usefulness of cannabinoids is limited because of their major toxic effects like dizziness, hallucination and dysphoria. Dysphoria specifically happens among older cancer patients who actually represent the largest proportion of cancer patients. These agents produce their antiemetic effect by acting directly on cannabinoids receptors found in the brain stem. Even so these agents are considered slightly better effective than conventional antiemetics agents such as metoclopramide, haloperidol and clopramide. These agents are more useful to be used in younger patients rather than in older cancer patients because they cause less euphoric and dysphoric side effects. Doses in the range of 5-10 mg/ m², every 3-4 hours orally will give the useful effect (Frytak *et al.*, 1979; Jordan *et al.*, 2005; Grunberg and Dugan, 2005; Mannix, 2004).

1.4.1.11.6 Benzodiazepines

They are usually used as an addition to antiemetic treatment to reduce anxiety due to chemotherapy treatment and the risk of anticipatory nausea and vomiting. Lorazepam is the preferred for anticipatory nausea and vomiting. Its anti-anxiety and sedative effect is very

useful when added to combination of antiemetic treatments, but its use as a single antiemetic is limited. Dose for Lorazepam usually is 1 to 2 mg every 6 hours for I.V. and 1 to 2 mg every 6 hours for oral administration (Jordan *et al.*, 2005; Kris *et al.*, 1985; Kris *et al.*, 1987).

1.4.1.12 Antiemetic guidelines for Acute and Delayed Chemotherapy Induced Nausea and Vomiting

The main guidelines used for the treatment of acute and delayed nausea and vomiting is shown in Table 2 below.

Table 1.2: Antiemetic Guideline for Acute and Delayed Nausea and Vomiting

Degree of Emetogenicity	Acute Emesis (Day 1)	Delayed Emesis (days 2-5)
High	Dex+NK1+5-HT ₃	Dex+NK1
Moderate	Dex+NK1+5-HT ₃ or Dex+5-HT ₃	Dex alone or 5-HT ₃ alone or metoclopramide alone or Dex+NK1
Low	Dex	Non
Minimal	Non	Non

5-HT₃= 5-HT₃ receptor antagonist, Dex= dexamethasone, NK1= neurokinin receptor antagonist(MASCC, 2004; Grunberg and Dugan, 2005; Morrow, 1985).

1.4.1.13 Nausea and Vomiting in Breast Cancer

Breast cancer is considered as the most common type of cancer among women and is the highest type of cancer in United Kingdom. It comprised 30.4% of all the cases of cancer occurrence in Malaysia in 2002. It was reported that 200,000 new cases were diagnosed in each year and about 46,000 women die because of breast cancer in United State of America (USA) each year (Chang and Lo, 2003; Jones *et al.*, 2007; Rhodes and McDaniel, 2001; Brookes *et al.*, 2007).

Metastasis is one of the main characteristic of breast cancer in advanced stages. About 50% of the cases have the ability to metastasis to different organs mainly to liver, stomach, colon, lung, brain, small bowel and skeleton. Metastasis to the stomach and brain may occur after several years from the first chemotherapeutic treatment i.e., when the breast cancer became the advanced stage (between 2 to 5 years following its diagnosis). The metastasis to the brain will cause several problems and the most important are gut disturbance, headache, seizure, nausea and vomiting. While the metastasis of the advanced breast cancer to the stomach will lead to the incidence of stomach cancer which could then lead to several gastrointestinal problems such as delay in gastric emptying and bowel obstruction. All these effects lead to nausea and vomiting (Chang and Lo, 2003; Jones *et al.*, 2007; Rhodes and McDaniel, 2001; Brookes *et al.*, 2007). About 60 to 75% of patients who have advanced stages of breast cancer also suffer from bone metastasis leading to incidence of hypercalcemia which would cause nausea and vomiting (Lipton, 2003).

Most of the chemotherapeutics agents used for treatment of breast cancer have an emetogenic potential that ranged between low (e.g., 5-fluorouracil and gemcitabine) to moderate (e.g., cyclophosphamide and anthracyclines). Despite the physician having several effective and adequate antiemetic agents (5-HT₃ and NK-1 receptors antagonists) in preventing nausea and vomiting, nevertheless significant proportion of breast cancer patients still suffer from nausea and vomiting after chemotherapy (Booth *et al.*, 2007; Choi *et al.*, 2005; O' Shaughnessy, 2003; Hesketh, 2005). There are so many studies which focused on nausea and vomiting but very few of them are prospective observational studies in breast cancer exclusively that looked for the main risk factors associated with nausea and vomiting (Hesketh, 2005; Osoba, 2005).

Besides that, there are many studies looking at the effect of nausea and vomiting associated with chemotherapy use on patients quality of life but there are few if any that investigated the effect of nausea and vomiting associated with solid cancer stages on patients quality of life (Hesketh, 2005; Rhodes and McDaniel, 2001). Choi *et al.* (2005) indicated that the

adjuvant chemotherapy {cyclophosphamide + methotrexate + 5-fluorouracil (CMF) and cyclophosphamide + epirubicin + 5-fluorouracil (CEF)} used for breast cancer patients caused nausea and vomiting. Anthracyclines is one of the most common agents used for breast cancer treatment but their clinical uses are limited due to acute nausea and vomiting, alopecia, neutropenia, anemia and thrombocytopenia. So many of these breast cancer patients showed severe nausea and vomiting which lead to a decrease in about 50% of the chemotherapy doses especially those who were treated with cyclophosphamide + methotrexate + 5- fluorouracil (CMF). Also due to the nausea and vomiting a high percentage of the breast cancer patients contemplate of stopping the chemotherapy (Booth *et al.*, 2007; Choi *et al.*, 2005; O' Shaughnessy, 2003; Hesketh, 2005).

1.4.1.14 Ethnic Variation Role in Incidence of Nausea and Vomiting

Interindividual diversity in drug metabolism is caused by many factors including environmental factors, cultural factors related with type of diet, concomitant drug therapy as well as genetic factors i.e., ethnic variation. All of these variations play an important role in changing pharmacokinetic and pharmacodynamic properties, volume of distribution, elimination, disposition and clinical effect for many drugs (Gross *et al.*, 1999; Ruzilawati *et al.*, 2007). Much of this distinction has shown to be caused by alteration of the human cytochrome P450 enzymes (CYP) (Ruzilawati *et al.*, 2007). CYP is the most vital enzymatic system concerned with drug metabolism. Approximately 65% of common drugs used are metabolized by cytochrome P450 enzymes and half of them are mediated by the CYP3A subfamily (Ruzilawati *et al.*, 2007). The CYP3A subfamily consists of 4 members: CYP3A4, CYP3A5, CYP3A7 and CYP3A47 and represents about 30% of the total CYP in the human liver. The most superior subfamily among the 4 types that play the major role in metabolism of more than 60% of all drugs used in human is CYP3A4 (Ruzilawati *et al.*, 2007). Miscellaneous CYP3A4 alleles in the population may partake in interindividual variability in CYP3A4 activity (Ruzilawati *et al.*, 2007). In case of cancer patients nausea and vomiting can be clinically significant and severely incapacitating side effects of cytotoxic

chemotherapy (Aapro, 2004). These symptoms can symbolize a major therapeutic challenge and if unsatisfactorily controlled by antiemetic treatment, will limit a patient's ability or desire to eat and drink, considerably reduce quality of life, threaten the success of therapy, and result in increased mortality, morbidity, and prominently health care costs (Aapro, 2004). The management of nausea and vomiting has enhanced greatly in recent years, with the utilization of 5-HT₃ (serotonin₃)-receptor antagonists (Bloechl-Daum *et al.*, 2006). These agents in combination with corticosteroids have been instrumental in improving the control of vomiting among patients receiving chemotherapy (Bloechl-Daum *et al.*, 2006). All 5-HT₃ receptor antagonists are metabolized by the cytochrome P-450 enzymes: tropisetron and dolasetron predominantly by CYP2D6, ondansetron partially by CYP2D6 but also by CYP3A4, CYP2E1, or CYP1A2, and granisetron mainly by CYP3A4 (Kaiser *et al.*, 2002). Even so there is significant percentage of cancer patients who do not respond well to 5-HT₃ receptor antagonists. The most important cause for such individual variation in drug response may be differentiation in drug biotransformation by genetically polymorphic enzymes, such as the hepatic cytochrome P-450 enzyme subfamily (Kaiser *et al.*, 2002).

Granisetron is an influential and highly selective 5-HT₃- receptor antagonist that has little or no attraction for other 5-HT receptors, or dopaminergic, adrenergic, benzodiazepine, histaminic, or opioid receptors. In contrast, other 5-HT₃- receptor antagonists have affinities for diverse receptor-binding sites (Bloechl-Daum *et al.*, 2006). For example, ondansetron has obvious binding to 5-HT_{1B}, 5-HT_{1C} and μ -opioid receptor sites. Although not proven, the binding of these agents to extra receptor subtypes other than their target receptor may lie beneath the inferior adverse-event profile seen with ondansetron compared with granisetron (Bloechl-Daum *et al.*, 2006).

1.4.1.15 Literature Review for Nausea and Vomiting

Warr mentioned in his study that both nausea and vomiting are the major problems that more than half of the cancer patients population will suffer from, either by the effect of cancer disease itself or chemotherapy. He mentioned that because of the closeness between nausea and vomiting many of the cancer patients express them as one symptom. Also Warr mentioned that some times one symptom will occur or take place without the other like for mild to moderate nausea it will not be accompanied by retching or vomiting. While patients with brain metastases and esophageal obstruction suffer from vomiting without preceding nausea. Warr showed that the physiology of nausea is still not clear and thus the prevention of vomiting is much easier than nausea. In his study he mentioned that nausea and vomiting occur in cancer patients either because of the cancer itself or because of the chemotherapy. But when cancer is the main cause this will required many investigations such as careful history, laboratory tests and physical examination in order to determine the underlining causes for nausea and vomiting with cancer so as to treat them correctly. Before 1980s a very high percentage of cancer patients treated with cisplatin or doxorubicin suffered from nausea and vomiting but the discovery and use of 5-HT₃ receptor antagonist with corticosteroids in 1990, had somewhat solved and prevent the occurrence of nausea and vomiting. However till now nausea and vomiting is still considered as a serious problem (Warr, 2008).

While Antonarakis and Hain (2004) described the effect of the chemotherapeutics drugs on the body cells is very harsh and thus the body will expel them as soon as possible by inducing nausea and vomiting. They also described nausea and vomiting as the most intractable, unpleasant and disgusting side effect suffered by many cancer patients especially children. Thus this emphasized that there are many risk factors related with patients that play a major role in nausea and vomiting incidence and severity including being female, young age, anxiety, motion sickness and poor control with previous chemotherapy. They also reported that risk factors responsible for nausea and vomiting incidence and severity associated with chemotherapy itself, route of administration, schedule and rate of

administration and the most important factor is the intrinsic emetogenicity factor of the chemotherapy itself. Thus the chemotherapy drugs are classified according to their emetogenicity.

Jordan *et al.* (2005) discussed the use of 5-HT₃ and dexamethasone and considered that their use since 1990s has led to the control of acute (70%) and of delayed emesis (40%) among cancer patients treated with highly emetogenic chemotherapy. She and her colleagues also reported that NK1 receptor antagonist offered a very effective protection against nausea and vomiting especially the delayed phase. Apart from NK1 others antiemetic drugs are also available for protection against emesis.

It has been noticed that there is a strong association between gender and occurrence of nausea and vomiting as gender is one of the risk factors for onset of both symptoms. Thus it has been reported that female is less responsive to antiemetic treatment than male and the main reason leading to the reduced antiemetic drug effect among female is the polymorphism of genes regulating the serotonergic system. Another factor considered as a risk factor for nausea and vomiting is race whereby it was reported that the incidence of nausea and vomiting associated with chemotherapy use among Asian cancer patients is much higher than those African and Caucasian cancer patients (Klosterhalfen *et al.*, 2005).

Age also plays a role in the incidence and severity of nausea and vomiting since it has been found that nausea and vomiting occurrence and severity is more among the younger patients as compared to the older patients (age > 50 years old). Other risk factors associated with incidence and severity of nausea and vomiting are prior history of nausea and vomiting with chemotherapy and alcohol consumption. The incidence and severity were reported to be more in patients with uncontrolled nausea and vomiting history and among patients who do not drink alcohol (Cancer care Nova Scotia, 2004/ www.cancercare.ns.ca/).

A pilot study by Grote *et al.* 2006 in 5 oncology centers in USA involving a total number of 58 cancer patients reported that 47% of them were women with breast cancer and

52% were treated with cyclophosphamide based chemotherapy. The main objective of their study was to evaluate the efficacy of 5-HT₃ receptor antagonist i.e., palonosetron plus dexamethasone and aprepitant. The main results of this pilot study were that the main response towards this antiemetic combination was great. The proportion of those with no vomiting during the acute phase (0-24 hours) was 88%, while for those with delayed response (> 24-120 hours) was 78%. Also reported that 90% of the patients have no vomiting during the whole time interval and between 57% to 71% of the patients did not vomit during the 5 days post chemotherapy period. There were also no nausea incidence. So the main conclusion Grote and his colleagues reached was that the combination of antiemetic treatment for the prevention of both nausea and vomiting of moderate chemotherapy treatment was good and effective.

Booth *et al.*, (2007) made a prospective study on 143 breast cancer patients in Canada and reported that most of them (91%) suffered from early stages of breast cancer. The mean age of the patients was 51.4 years that ranged from 24 to 76 years. The patients received 766 cycles of chemotherapy (range 1-6 cycles; median= 3 cycles) and the main chemotherapy used was anthracyclines. Booth and his colleagues mentioned that the chemotherapy used in breast cancer treatment were either low emetogenic chemotherapy (taxanes, gemcitabine and 5-fluorouracil) or moderate emetogenic chemotherapy (cyclophosphamide and anthracyclines). In the first 24 hours, very few patients (10%) showed severe (i.e., grade 4) nausea and vomiting, but in the delay phase 70% of the patients developed grade 1 - 3 nausea. Unlike most studies, this prospective study focused on all the 6 cycles of chemotherapy and reported that the prevalence of nausea and vomiting was insignificantly affected by multiply cycles of chemotherapy. The differences in the grades of nausea and vomiting either acute or delayed associated with chemotherapy happened within the first cycle. In their study it was also observed that very few patients suffered from severe nausea and vomiting (i.e., < 10%). This could be because most of the patients were at the early stage of breast cancer and were treated with anthracyclines chemotherapy which has moderate

emetogenic potential and also they were treated with an effective antiemetic treatment (NK-1 antagonist). The major symptom observed in this study was delayed nausea (70%) which emphasized the difficulty to control such symptom as compared to vomiting.

Bloechl-Daum *et al.* (2006) accomplished a prospective, multicenter and multinational study in Denmark on 298 cancer patients treated with highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC). They suffered from different types of cancer but breast and lung cancer were the most common type. The main objective for this study was to determine the impact of CINV on patients QOL. Data collection process was done by using functional living index- emesis (FLIE) questionnaire. The main results of this study was that CINV continue to adversely effects cancer patients QOL, especially nausea which has a greater negative impact on QOL than vomiting. This study mentioned that it is very important to find or develop a new antiemetic regimen and suggested that studies should investigate and examine the effectiveness of new antiemetic guideline by ASCO in reducing or preventing the negative impact of CINV on cancer patients QOL.

Cohen *et al.* (2007) conducted a study in California, USA on 151 cancer patients. Fifty-five percent of them were breast cancer patients followed by patients with lymphoma, lung and other different types of cancer. The patients were from different races and ethnicity. The main objectives of their study were to determine the prevalence of acute and delayed nausea and vomiting caused by chemotherapy treatment and to evaluate their effect on patients. The data were collected from cancer patients who were scheduled for the first cycle of new chemotherapy regimen and the occurrence of CINV were recorded by completing a daily dairy and the Functional Living Index-Emesis (FLIE tool). The main result was that CINV has a direct effect on cancer patients QOL.

The main differences between these two studies and present study is that they were just looking for the negative impact of CINV on cancer patients QOL with different types of chemotherapy regimens and different types of cancer but did not look at the main risks factors for nausea and vomiting onset and severity which was performed in **our** study.

Besides that present study will also try to find the main impact of delayed CINV on breast cancer QOL. Also the FLIE questionnaire employed by the researchers only focused on the assessment of cancer patients QOL, but not related with the effectiveness of antiemetic treatments. While present study will be focusing on specific type of solid cancer, specific chemotherapy regimens, main risk factors for nausea and vomiting onset and severity, effectiveness of the antiemetic treatments and on the main impact of CINV i.e., acute and delay on cancer patients QOL. This present study also used a mix questionnaire of MANE and ONEM to look for the two main parameters which are the effectiveness of antiemetic treatment and the impact on QOL. According to the World Health Organization (WHO), the definitive goal for palliative care is the achievement of the best QOL for cancer patients which could be accomplish by distinguishing the main risk factors, proper treatment and symptoms (Beijer *et al.*, 2008) which are the main emphasis of present study.

Glaus *et al.* (2004) also conducted a prospective cross-sectional study on 249 cancer patients from several centers in Spain, Germany, Austria and Switzerland. The main aim of their study was to evaluate the incidence of moderate to severe emetogenic chemotherapy induce nausea and vomiting and their effect on patients daily life activities. About 78% of the patients were women, with a mean age of 54 years old. Breast, lung and ovarian cancers were the most predominant cancer and each patient was treated with 2.0 types of chemotherapy agents and 2.5 types of antiemetic drugs. The main results were that delayed emesis was the highest in incidence (38%) as compared to acute emesis. Even in those patients treated with adequate antiemetic treatment delayed emesis incidence was still high. The main explanation given was patients were not treated optimally for delayed emesis or may be because they were treated with cyclophosphamide. Another explanation given was that the neurological control for delayed and acute emesis are distinctly different from each other, and therefore the main control of risk factor for delayed emesis incidence is still unclear.